**SUPPLEMENTARY FIGURE LEGENDS**

**Figure 1** Staining of fourPD-L1 antibody clones in human placenta tissue (x 200): **A**, Ventana SP263; **B**, SP142; **C**, E1L3N; **D**, 405.9A1.

**Figure 2** Staining of threePD-L1 antibody clones in “sausage” test block: Left panel: benign prostatic tissue (x 200); Right panel: colon medullary carcinoma (x 400). **A** and **D**, Ventana SP263; **B** and **E**, SP142; C and F, E1L3N.

**Figure 3** Staining of threePD-L1 antibody clones in two cases of untreated PCa that were PD-L1-positive (x 400): Left panel: Case UN69 (blue arrow: nerve); Right panel: Case UN88. **A** and **D**, Ventana SP263; **B** and **E**, SP142; **C** and **F**, E1L3N.

**Figure 4** Staining of threePD-L1 antibody clones in two cases of Neo-AAPL treated PCa that were PD-L1-positive (x 400): Left panel: Case A31; Right panel: Case A7. **A** and **D**, Ventana SP263; **B** and **E**, SP142; **C** and **F**, E1L3N.

**Figure 5** PD-L1 expression in six tumors with staining in 1-4% tumor cells: E1L3N (x 600). **A-C,** “scattered” pattern: **A,** Case UN8**. B,** Case UN97**; C**, Case UN116; **D-F**, PD-L1high component in cases of “nodular” pattern: **D,** Case UN69; **E,** Case UN75; **F**, Case UN94.

**Figure 6 A,** Dual immunostain for PD-L1 (E1L3N, brown chromogen) and CK18 (red chromogen) of a tumor (case UN116) with PD-L1 staining in 1-4% tumor cells (x 1,000); **B-D,** Two adjacent tumor nodules (Case UN125) that were discordant for PD-L1 but concordant for ERG and PTEN on immunostains (x 100): **B**, PD-L1; **C,** ERG; **D,** PTEN.

**Figure 7** Correlation of PD-L1 expression with tumor-infiltrating CD8+ T cells and PD-1+ cells in two Neo-AAPL treated tumors (x 400): **A-C**, a PD-L1-positive tumor (case A7) (**A**, PD-L1; **B**, CD8; **C**, PD-1); **D-F**, a PD-L1-negative tumor (case A3) (**D**, PD-L1; **E**, CD8; **F**, PD-1).

**Figure 8** The densities of tumor-infiltrating immune cells that were positive for CD3, CD8, and PD-1, per 100 tumor cells, were plotted in PD-L1- positive and -negative cases (N =14), regardless of treatment status (upper panel), with or without Neo-AAPL treatment (bottom panel).